Home Gains Buoy Cipla In Q1 But US Momentum Pivotal
A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.
You may also be interested in...
Cipla rang in a “modest” Q2 and management has cautioned that coming quarters might see significant headwinds including the impact of a constrained funding environment on the tender business and US sanctions-related turbulence in some markets.
Dr Reddy’s Laboratories appears to be the among the Indian firms considering increasing its activities in China, enthused by the evolving regulatory environment and consequent market opportunities there. The Indian company believes a large basket of products could meet China’s new norms.
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.